Literature DB >> 27496304

Hodgkin lymphoma: Pathology and biology.

Stephan Mathas1, Sylvia Hartmann2, Ralf Küppers3.   

Abstract

The Hodgkin and Reed-Sternberg (HRS) tumor cells of classical Hodgkin lymphoma (HL), as well as the lymphocyte predominant (LP) cells of nodular lymphocyte predominant HL (NLPHL), are derived from mature B cells. However, HRS cells have largely lost their B-cell phenotype and show a very unusual expression of many markers of other hematopoietic cell lineages, which aids in the differential diagnosis between classical HL (cHL) and NLPHL and distinguishes cHL from all other hematopoietic malignancies. The bi- or multinucleated Reed-Sternberg cells most likely derive from the mononuclear Hodgkin cells through a process of incomplete cytokinesis. HRS cells show a deregulated activation of numerous signaling pathways, which is partly mediated by cellular interactions in the lymphoma microenvironment and partly by genetic lesions. In a fraction of cases, Epstein-Barr virus contributes to the pathogenesis of cHL. Recurrent genetic lesions in HRS cells identified so far often involve members of the nuclear factor-κB (NF-κB) and JAK/STAT pathways and genes involved in major histocompatibility complex expression. However, further lead transforming events likely remain to be identified. We here discuss the current knowledge on HL pathology and biology.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Germinal center; Hodgkin lymphoma; LP cell

Mesh:

Substances:

Year:  2016        PMID: 27496304     DOI: 10.1053/j.seminhematol.2016.05.007

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  50 in total

1.  Lymphoma Mimicking Chronic Active Epstein-Barr Virus: A Case Report.

Authors:  Rohini Bahethi; Mingyang Gray; Christian Salib; Ilya Likhterov
Journal:  Head Neck Pathol       Date:  2020-04-29

Review 2.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

3.  Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.

Authors:  Enrico Tiacci; Erik Ladewig; Gianluca Schiavoni; Alex Penson; Elisabetta Fortini; Valentina Pettirossi; Yuchun Wang; Ariele Rosseto; Alessandra Venanzi; Sofija Vlasevska; Roberta Pacini; Simonetta Piattoni; Alessia Tabarrini; Alessandra Pucciarini; Barbara Bigerna; Alessia Santi; Alessandro M Gianni; Simonetta Viviani; Antonello Cabras; Stefano Ascani; Barbara Crescenzi; Cristina Mecucci; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  Blood       Date:  2018-04-12       Impact factor: 22.113

4.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Authors:  Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

Review 5.  Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.

Authors:  W Robert Liu; Margaret A Shipp
Journal:  Blood       Date:  2017-11-23       Impact factor: 22.113

6.  Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.

Authors:  Amy S Duffield; Maria Libera Ascierto; Robert A Anders; Janis M Taube; Alan K Meeker; Shuming Chen; Tracee L McMiller; Neil A Phillips; Haiying Xu; Aleksandra Ogurtsova; Alan E Berger; Drew M Pardoll; Suzanne L Topalian; Richard F Ambinder
Journal:  Blood Adv       Date:  2017-07-21

Review 7.  Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.

Authors:  W Robert Liu; Margaret A Shipp
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

8.  Incidence, clinical presentation, and outcomes of Pneumocystis pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma.

Authors:  Jason N Barreto; Carrie A Thompson; Patrick M Wieruszewski; Amanda G Pawlenty; Kristin C Mara; Ashley L Potter; Pritish K Tosh; Andrew H Limper
Journal:  Leuk Lymphoma       Date:  2020-07-05

9.  Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

Authors:  Margaretha G M Roemer; Robert A Redd; Fathima Zumla Cader; Christine J Pak; Sara Abdelrahman; Jing Ouyang; Stephanie Sasse; Anas Younes; Michelle Fanale; Armando Santoro; Pier Luigi Zinzani; John Timmerman; Graham P Collins; Radhakrishnan Ramchandren; Jonathon B Cohen; Jan Paul De Boer; John Kuruvilla; Kerry J Savage; Marek Trneny; Stephen Ansell; Kazunobu Kato; Benedetto Farsaci; Anne Sumbul; Philippe Armand; Donna S Neuberg; Geraldine S Pinkus; Azra H Ligon; Scott J Rodig; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2018-02-02       Impact factor: 44.544

10.  The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma.

Authors:  Joji Nagasaki; Yosuke Togashi; Takeaki Sugawara; Makiko Itami; Nobuhiko Yamauchi; Junichiro Yuda; Masato Sugano; Yuuki Ohara; Yosuke Minami; Hirohisa Nakamae; Masayuki Hino; Masahiro Takeuchi; Hiroyoshi Nishikawa
Journal:  Blood Adv       Date:  2020-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.